On Thursday, Neurocrine Biosciences Inc. NBIX reported fourth-quarter adjusted EPS of $1.69, larger than the $1.54 reported a 12 months in the past, beating the consensus of $1.56.
The corporate reported gross sales of $627.7 million in comparison with $515.2 million a 12 months in the past, lacking the consensus of $628.99 million.
Ingrezza fourth quarter and financial 2024 web product gross sales have been $615 million and $2.3 billion, respectively.
Additionally Learn: Neurocrine Obtains Unique Rights For Despair Drug, Takeda Reacquires Japan Rights
Ingrezza fourth-quarter web product gross sales grew 23% in comparison with fourth quarter 2023, pushed by sturdy underlying affected person demand and enchancment in gross-to-net dynamics.
Crenessity fourth quarter and financial 2024 web product gross sales have been $2 million, reflecting preliminary pharmacy orders following FDA approval in December 2024
Steering: Neurocrine Biosciences expects 2025 Ingrezza Internet Product Gross sales of $2.5 billion-$2.6 billion.
William Blair writes that Ingrezza’s 2025 income steering is barely conservative in comparison with their 2025 estimate of $2.60 billion and the Road estimate of $2.67 billion, which fell beneath investor expectations.
Analyst Myles Minter writes that near-term pressures are weighing on the Ingrezza trajectory. The analyst continues to view Ingrezza because the gold-standard pharmacotherapy for tardive dyskinesia (TD), given its once-daily dosing, no want for lengthy dose titration intervals, and lack of a suicidality and melancholy FDA black-box warning.
With Ingrezza nonetheless holding 14 years of potential patent safety, William Blair sees a protracted progress trajectory for the product, however the mannequin addresses near-term aggressive pressures forward of the second-half 2025 salesforce growth.
William Blair reiterates the Outperform score on Neurocrine.
Analyst Response:
- BofA Securities analyst Tazeen Ahmad maintains Neurocrine Biosciences with a Purchase and lowers the worth goal from $184 to $179.
- Needham analyst Ami Fadia reiterates the Maintain score.
- HC Wainwright analyst Andrew Fein maintains Neurocrine Biosciences with a Purchase and lowers the worth goal from $190 to $185.
Worth Motion: NBIX inventory is down 191% at $121.98 on the final examine on Friday.
Learn Subsequent:
Overview Ranking:
Speculative
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
